Dong Sung Pharmaceutical Minority Shareholders' Alliance: "Shareholder Value Must Not Be Undermined for the Sake of Normalization"... Calls for Financial Supervisory Service Investigation
Minority shareholders of Dong Sung Pharmaceutical held a rally in front of the Financial Supervisory Service on March 13, arguing that the justification of normalizing the company should not be used as a means to legitimize the infringement of existing shareholders' rights.
They stressed that it must be clearly verified whether the rehabilitation plan and the acquisition efforts truly enhance the company's sustainability, or if they merely demand excessive sacrifices from minority shareholders.
The shareholders' alliance stated, "What is needed now is not the unconditional pursuit of M&A, but a transparent verification of which structure is genuinely beneficial for both shareholders and the company," and urged the Financial Supervisory Service to investigate whether minority shareholders are being harmed.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
They further emphasized, "Rehabilitation should be a process that saves both the company and its stakeholders; it should not be a structure where only minority shareholders are unilaterally burdened with losses."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.